SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025

Senti Biosciences, Inc.

5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.
No dose-limiting toxicities; preliminary RP2D set at 1.5x10^9 CAR NK cells Days 0,7,14 per 28-day cycle.
Longest ongoing response >8 months; 3 patients received bone marrow transplant after SENTI-202.
Q1 2025 preliminary: cash $33.8M, net loss $14.1M ($1.41/share); R&D $9.3M, G&A $7.1M.
SENTI-301A/SN301A HCC trial enrollment stopped due to dose-limiting toxicities; evaluating next steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.